Novartis hopeful for novel heart drug, despite ‘modest’ benefit

ZURICH, Aug 27 (Reuters) – Novartis will seekregulatory approval this year for a new kind ofanti-inflammatory heart drug, though some experts fear fatalinfection risks and a high price may overshadow the medicine’slimited benefits.
The post Novartis hopeful for novel heart drug, despite ‘modest’ benefit appeared first on RocketNews | Top News Stories From Around the Globe.